Roschier represents Orkla in the acquisition of VitaePro and Oslo Skin Lab
Orkla has entered into an agreement to acquire NutraQ, valued at NOK 3.1 billion at enterprise value, from Impilo and Sana Pharma Holding. The acquisition is subject to approval by relevant competition authorities. Roschier advises Orkla in the transaction.
NutraQ 2 AS is a leading supplier of health and beauty products, such as health and beauty concepts VitaePro and Oslo Skin Lab, Men’s Health brands Maxulin and Provexin and the Vesterålens Naturprodukter brand.
The company is headquartered in Oslo, Norway, and employs around 150 people. Its turnover in 2020 was NOK 862 million and the parties have agreed on a purchase price that values NutraQ at NOK 3.1 billion at enterprise value.
Orkla Health is one of Scandinavia’s leading branded consumer goods suppliers in categories such as cod liver oil, vitamins and other dietary supplements.
Roschier’s core advisory team comprises Jon Unnérus, Tero Jormanainen, Jenni Rosenlöf, Sara Karhu, Sonja Karikumpu, Ami Paanajärvi, Sari Rasinkangas, Iida Lindfors, Juho Ohisalo and Emmi Viitanen.